Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Technetium-99m labelled photosensitizer-peptide conjugate is a preclinical-stage theranostic radiopharmaceutical developed for cancer imaging and therapy. The agent is a peptide-drug conjugate consisting of a targeting peptide that binds to the gastrin-releasing peptide receptor (GRPR), conjugated to a ruthenium(II)-based photosensitizer (Ru-PS) and radiolabeled with technetium-99m. This bimodal design allows for single-photon emission computed tomography (SPECT) imaging to track the agent in vivo, combined with photodynamic therapy (PDT) to induce localized phototoxicity upon light irradiation. The platform also offers potential for radionuclide therapy by exchanging the diagnostic technetium-99m isotope with therapeutic rhenium-188.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on technetium-99m labelled photosensitizer-peptide conjugate.
Work on technetium-99m labelled photosensitizer-peptide conjugate? Claim this page to correct or add information. Claim this page